Among the different compounds used, only GF109203X (GFX), an inhibitor of classical and new PKCs, and U0126, a MEK1 inhibitor, dampened AXL expression in IM-R and PD-R CML cell lines (data not shown). The gene discussed is MAP2K1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.